The people we trust. And what they sell.

Overall philosophy, foundations before peptidesfair

Peptides are strictly additive and must sit ON TOP of non-negotiable basics: consistent sleep, morning sunlight, minimally-processed food, and regular training. Stacking peptides while the fundamentals are unaddressed is pointless. This is the foundational posture Ground Truth inherits from him.

Animal-vs-human evidence gap (the site's thesis)fair

The central honesty point: a large share of peptide efficacy evidence is animal-only, and the gap between dramatic animal results and thin human data is the defining uncertainty of the field. He frames receptor status as a key predictor, peptides with a known receptor (e.g. GLP-1s) behave predictably; those without (BPC-157, TB-500) are far less characterized.

BPC-157, evidence base and the single-group problemfair

Animal data is striking (tendon/ACL/burn/neuro healing via VEGF, nitric oxide, cell migration) but human data is almost nonexistent, essentially one small Croatian ulcerative-colitis trial program, full data unpublished, and the bulk of the literature comes from one research group. He treats this as a reason for caution, not dismissal.

BPC-157, standard dose is probably too lowthin

Suspects the commonly-injected ~100-250 mcg/day is too low because it derives from vendor/website recommendations rather than any human dose-finding study; the real effective human dose is unknown and likely higher.

BPC-157, under-discussed neuro/dopamine signalthin

Finds the neuropsychiatric reports (anecdotal anhedonia, flat affect, blunted dopamine/stimulant response) more interesting and important than the musculoskeletal use case, and flags them as an under-examined risk rather than a proven effect.

GHK-Cu, topical for skin, do not inject the facefair

Best-evidenced use is TOPICAL for skin photoaging, comparable to retinol/vitamin C; hair-growth data is weak (not a minoxidil replacement). Explicitly warns against injecting GHK-Cu into the face, and notes topical products lacking the blue copper color may have no active copper. Suggests pairing with a full routine / red-light therapy rather than standalone.

GLP-1 agonists, 'training wheels', not foreverfair

Advocates a 'training wheels' model: lowest effective dose, slow titration, paired with real lifestyle change, then taper off, not indefinite use. Attributes many reported negatives (mood/energy crashes) to under-eating, electrolyte depletion, and blood-sugar mismanagement rather than the drug. Calls some high-profile celebrity GLP-1 protocols clinically irresponsible due to poor monitoring.

GLP-1, long-term cognitive and fertility unknownsthin

Flags that current dosing pushes GLP-1 signaling far above normal physiology with no data on long-term effects on neuroplasticity/learning, and that GLP-1 receptors in the ovaries mean women considering pregnancy should discuss reproductive risks with a physician.

Growth-hormone secretagogues, cancer/IGF-1 caution; prefer pulsatilefair

Prefers tesamorelin (pulsatile, circadian-appropriate GH release) over MK-677 (large non-pulsatile GH dump, more side effects). Repeatedly cautions that GH/IGF-1 are pro-growth signals that could accelerate an unknown tumor, and that anyone with a prostate must monitor PSA (cites the Huberman sermorelin-PSA-spike anecdote).

Pinealon / Epithalon (Soviet bioregulators), interesting but lightly evidencedthin

Treats these as genuinely intriguing: pinealon reportedly boosts REM in late sleep with benefits persisting after stopping (he notes Huberman caps use at ~3x/month); epithalon may restore melatonin synthesis in aged (not young) animals and is tied to an old long-duration nursing-home mortality signal. Presents the human evidence as old, Soviet-era, and far from rigorous, a hypothesis-rich, proof-poor category.

Sourcing hierarchy, safest to riskiestfair

Ranks supply explicitly: standard pharmaceutical > quality compounding pharmacy > low-quality compounder > gray market ('research only', unpredictable batch-to-batch) > black market (never). Notes most buyers are unknowingly on the gray market, and that EVERY peptide active ingredient ultimately originates from Chinese manufacturers, there is no truly American-made peptide.

Gray-market scale and the 'e-commerce with a doctor's stamp' problemthin

Estimates the US gray-market peptide trade at roughly $5-10B/year and growing, and criticizes much of the telehealth peptide space as 'e-commerce with a doctor's stamp' rather than genuine clinical care. Notes affiliate marketing has exploded around peptides.

Regulatory / legal reality. BPC-157, malpractice, state boardsthin

Notes BPC-157 was moved to FDA Category 2 ('do not compound'), then removed but not restored to the approved Category 1, and that compounders quickly rebranded it as PDA (pentadecapeptide arginate). States that no malpractice insurer covers prescribing non-FDA-approved injectable peptides, and that some state medical boards bar them regardless of FDA status, a candid look at the legal exposure clinicians carry.

Compounding-pharmacy markup ('dirty secret')thin

Advises patients to ask their prescriber both the pharmacy COST and the retail CHARGE for a compounded peptide, because physicians often buy at cost and mark up arbitrarily without the patient knowing, a consumer-protection point against the prescribing side of the market.

Thymosin alpha-1 / thymic peptides, personal use and immune framingthin

Uses thymosin alpha-1 himself (injects ~twice weekly while traveling or doing hospital work) and frames thymic health as an underrated longevity lever, points to CD4/CD8 ratio and naive T-cell counts on labs, and thymic tissue visible on full-body MRI, as practical signals. Notably this is one of the few peptides where he speaks from personal protocol rather than caution.

Melanotan / counterfeit supply as a cautionary talethin

Cites a case of a gray-market 'tirzepatide' that turned out to be melanotan 2 (caused skin darkening) to illustrate identity fraud and batch unpredictability in unregulated supply, i.e. you often don't get what the label says.

Enhanced Games GHK-Cu, promotional posture (CONFLICT)well-sourced

In the commercial setting (not the educational one), he lends his name to Enhanced's prescription topical GHK-Cu launch, quoted that GHK-Cu has been studied for decades as a regulator of skin biology and collagen synthesis. Useful to log as the spot where his educational caution and a commercial interest sit on the same molecule.

Overall framing, peptides as a 'safe' middle tierwell-sourced

Frames peptides as a generally very safe tool with rare negative side effects when properly sourced and physician-supervised, a middle ground between lifestyle basics and aggressive pharmaceuticals, suitable for essentially any adult working on some facet of their health. Our read: this 'very safe' framing is more confident than the thin human-trial base for most of these compounds supports, and it understates the animal-vs-human evidence gap.

BPC-157well-sourced

Describes BPC-157 as a potent anti-inflammatory useful for exercise recovery, gut regulation, and possibly upregulating growth-hormone receptors; says injectable outperforms oral (oral mostly gut-limited) and can be injected directly into a tendon for healing within days. Suggested starting ~500 mcg/day, titrate up, cycle 5 days on / 2 off. Notes it was pulled from compounding availability after the FDA action.

Pentadeca Arginate (PDA) as BPC-157 successorwell-sourced

Positions PDA as a near-identical successor to BPC-157 (essentially one substitution, arginate for acetate) that his clinic is seeing comparable anti-inflammatory clinical responses from, becoming relevant precisely because BPC-157 was placed on the FDA 'difficult to compound' (Category 2) list. Suggested 250–500 mcg/day, Mon–Fri. Our read: this is a clinical-anecdote claim, not trial-backed.

Growth-hormone secretagogues (Ipamorelin / CJC-1295 / Sermorelin / Tesamorelin / GHRP-6 / Hexarelin)well-sourced

Favors stimulating the body's own GH release over exogenous HGH. Calls ipamorelin the most specific but weakest secretagogue (cap ~100 mcg, dose at bedtime to catch the ~10pm–2am GH window), commonly paired with CJC-1295 to prolong circulation; sermorelin dosed by goal; tesamorelin (~2 mg) for visceral fat, noting it works better in women; GHRP-6 (~100 mcg) for mass but with cortisol/hunger drawbacks; hexarelin (~100 mcg) in the morning for an energy burst.

NAD+ (and NMN / NR)well-sourced

His single highest-conviction intervention, says if he had to pick one thing for people it would be NAD. Argues oral NAD is poorly absorbed so prefers IV (~750 mg loading dose, then monthly maintenance), with injectable second-best and NMN as a cheaper fallback; rates NR as weakest. Claims dramatic anecdotal recovery effects (e.g., COVID within ~48 hrs) while acknowledging the mechanism isn't fully explained and infusions are expensive (~$500–1000) and can cause nausea. Repeatedly claims to have overseen more NAD+/peptide therapy than any physician in the world.

GLP-1 agonists (semaglutide etc.)fair

Supportive when used safely and effectively; frames them as able to reduce adipose-tissue inflammation and catalyze behavior change, but recommends micro-dosing to target roughly ~2 lb/week to limit muscle loss, and flags cost, dependency potential, and that the behavior change isn't guaranteed.

Sourcing & physician oversight (his core safety thesis)well-sourced

His most consistent message: only use peptides obtained through a physician you've actually met who monitors dosing and response, and via regulated compounding pharmacies, warning that gray-market 'research-only / not for human consumption' product is often impure or contaminated with inflammatory lipopolysaccharides and has caused severe reactions. Also flags that the 2023 FDA Category 2 listing cut off compounding-pharmacy access for several peptides.

Methylene bluefair

Recommends it as a mitochondrial/cognitive enhancer, oxygenator, and antiviral, roughly 10 mg in the morning ~3x/week, noting good oral uptake and the temporary blue-tongue effect.

Testosterone / hormonesfair

Prescribes bioidentical hormones but cautions that exogenous/synthetic testosterone risks fertility loss and that black-market sourcing damages long-term sperm quality; notes physician monitoring is essential. Mentions deca-durabolin as the only FDA-approved anabolic usable alongside testosterone.

Sleep / cognitive peptides (Pinealon, Cerebrolysin, Epitalon, Thymosin Alpha-1)fair

Discusses pinealon (with glycine) for REM/sleep, cerebrolysin for cognition/brain injury via increased BDNF (with a possible transient 1–2 day low mood), epitalon for DNA-repair/longevity (acknowledging minimal human data), and thymosin alpha-1 for immune modulation (noting it lost FDA-approved status), generally pairing strong mechanistic enthusiasm with admissions that human data are limited.

Peptides as a class (overall thesis)well-sourced

Peptides are a legitimate and powerful therapeutic class, but that legitimacy is confined to a relatively narrow subset; he frames the goal as neither promoting nor dismissing them wholesale, but giving listeners a repeatable framework (mechanism, evidence quality, safety, dosing, alternatives) to judge any given peptide.

Peptide triage framework (the 'buckets')fair

In AMA #83 he sorts peptides into numbered tiers: roughly Bucket 1 = weakest/avoid (BPC-157), Bucket 2 = intermediate caution (CJC-1295, melanotan-II), Bucket 3 = more nuanced risk-reward (SS-31/elamipretide), Bucket 4 = oral peptides limited by absorption, explicitly separating gray-market longevity peptides from FDA-approved peptide drugs.

BPC-157fair

Places BPC-157 in his weakest tier: origins are uncertain, the marketed claims are broad, mechanistic evidence is weak, and the encouraging animal data has not replicated in humans, so the human evidence does not justify the hype. Treated as a cautionary example, not an endorsement.

Growth-hormone secretagogues / GHRH peptides (CJC-1295, ipamorelin class)fair

Assigns GH-secretagogues like CJC-1295 to an intermediate-caution tier: the GH-stimulating mechanism is understood, but human data is limited, dosing is uncertain, and long-term safety is unestablished, so caution dominates.

Insulin and GLP-1 drugs as the legitimate peptidesfair

Points to insulin (discovered ~100 years ago, essential in type 1 diabetes) and the GLP-1 receptor agonists as the most important, genuinely FDA-approved peptide therapeutics, the benchmark of legitimacy against which gray-market peptides should be measured (noting GLP-1 drugs are engineered analogs, not the exact endogenous peptide).

Gray-market sourcing, 'research use only' labeling, and regulationfair

Warns that gray-market peptides are sold under 'research use only' labeling while actually being injected by humans, that purity and identity cannot be fully guaranteed even with third-party testing, and that these compounds lack FDA approval and meaningful regulatory oversight.

Rapamycin for longevitywell-sourced

Takes rapamycin himself (intermittent low weekly dosing, cycled) but consistently classifies it as 'promising, not proven': strong animal data and a plausible mTOR/autophagy mechanism, yet no meaningful long-term human outcome data, so he explicitly declines to call it geroprotective in humans.

Rapamycin, holding the line as evidence arrivesfair

When the first rapamycin-plus-exercise human trial (RAPA-EX) disappointed, rapamycin did not enhance, and may have modestly blunted, training adaptations, he treated it as confirmation that current human evidence does not support healthspan/lifespan claims, rather than walking back to defend prior enthusiasm.

Testosterone / TRT dosingfair

Frames testosterone as physiologic replacement, not enhancement: says he has prescribed testosterone cypionate conservatively (on the order of never more than ~150 mg/week), explicitly contrasting that with the 1,500-2,000 mg/week bodybuilding protocols his guest Derek described.

Evaluating any exogenous molecule (general method)fair

Applies one consistent decision framework to drugs, hormones, supplements and peptides alike: define the objective clearly, identify a biomarker to track effect, then judge whether benefit outweighs risk based on mechanism, patient-years of use, and short- and long-term safety, a harm-reduction, case-by-case posture rather than categorical approval or rejection.

IGF-1, the GH axis, and cancer riskthin

Has long engaged the insulin/IGF-1 pathway as a driver of cancer and aging biology, which underlies his caution toward chronically raising GH/IGF-1 via secretagogues, i.e. the same axis that makes 'more growth signaling' a double-edged longevity tradeoff.

BPC-157 (injectable), personal usewell-sourced

Has stated on his own X account that he has personally experimented with BPC-157 (alongside Cerebrolysin) over the years, but says he now primarily uses topical peptides on his hair and skin. Frames injectable BPC-157 as something he has cycled through rather than a current daily staple.

BPC-157 + TB-500 for acute injuryfair

Documented using BPC-157 with TB-500 (TB4) daily for roughly 20 days to rehab a sprained ankle with a small fracture, sharing his reconstitution and dosing in a public thread. Presents peptides as a tool inside a structured injury-recovery protocol, not a casual add-on.

Peptides, overall posture / efficacy + evidence gapwell-sourced

Says peptides are effective 'when used precisely' but openly cautions that research is limited for many of them, making blanket recommendations hard. This is a notably hedged, evidence-aware stance that lines up with the animal-vs-human data-gap thesis rather than peptide hype.

Topical / cosmetic peptides (current protocol)well-sourced

His own published Blueprint protocol lists a topical hair serum with eight biomimetic peptides (including Thymosin-β4, Copper Tripeptide-1, EGF, and others) plus daily collagen peptides (~11g+ at meals). These, not injectables, are the peptides he currently centers, and they are also products he sells.

Follistatin gene therapy (adjacent to peptides)well-sourced

Underwent experimental follistatin gene therapy in Honduras (Sept 2023) and published his own data claiming a ~160% rise in follistatin levels and later muscle-mass gains. Presented as personal n=1 data, NOT peer-reviewed, and he frames it as ongoing experimentation requiring monitoring.

GLP-1 / tirzepatide microdosingwell-sourced

Trialed microdosing tirzepatide for possible longevity benefit and reported it raised his resting heart rate (~3 bpm) and hurt sleep, so he weighed the trade-off against his biomarkers publicly. Acknowledges GLP-1s can solve otherwise-intractable food addiction while remaining wary of the cardiovascular cost.

Rapamycin, stopped after ~5 yearswell-sourced

Discontinued rapamycin (stopped ~Sept 2024, announced Jan 2025) after nearly five years, citing side effects (skin/soft-tissue infections, lipid and glucose abnormalities, elevated resting heart rate) and a preprint suggesting it accelerated epigenetic aging across multiple clocks. A clear case of him killing an intervention when the data turned against it, the same bar this site applies to peptides.

Direct peptide commentary (BPC-157, GHK-Cu, GLP-1, etc.)thin

GENUINE GAP / NOT ON RECORD. Repeated targeted searches for Saladino paired with specific peptides (BPC-157, collagen, copper peptide, GLP-1/semaglutide) surfaced no substantive on-record statement from him about peptide therapy. His public output is built around food and natural hormone optimization, not peptides. Treat his peptide footprint as effectively absent rather than positive or negative.

Exogenous testosterone / TRTwell-sourced

Says he has personally never used TRT or pharmaceutical testosterone, and argues most men in their 40s-60s do not need it. Warns that exogenous testosterone shuts down the body's own production and can create long-term dependency that is hard to reverse. Frames TRT as a last resort after root causes are addressed.

PEDs / performance-enhancing drugs (personal use)fair

States he does not use performance-enhancing drugs and has 'never touched TRT or any other drugs,' positioning his own physique and high testosterone as the product of diet and lifestyle rather than pharmacology.

How to raise testosterone (the alternative he sells instead)well-sourced

Advocates raising testosterone naturally via an animal-based diet (meat, organs, fruit, honey, raw dairy for zinc, vitamin A, boron), removing seed oils and processed food, prioritizing sleep, resistance training, sun/grounding, and removing endocrine disruptors. Cites his own labs (~560 to ~860 ng/dL) as proof. Markets organ-based supplements (Heart & Soil) as a hormone-support tool.

GLP-1 weight-loss drugs (Ozempic / semaglutide)thin

DIRECTIONAL ONLY. UNVERIFIED. Third-party clip titles frame him as warning against Ozempic (weight regain after stopping). Could not confirm his actual argument from a primary source, so this is flagged as a likely-but-unverified position consistent with his anti-pharma, fix-the-root-cause posture, not a confirmed quote.

Diet evolution (carnivore to animal-based)well-sourced

Publicly reversed his strict carnivore stance around 2020-2024, reporting that long-term ketosis caused him sleep disturbances, heart palpitations, cramps and LOWERED testosterone. Now promotes an 'animal-based' diet that adds fruit, honey and raw dairy. Relevant because it shows he will publicly change a flagship position when his own biomarkers contradict it.

Sourcing & purity (LPS contamination)well-sourced

Repeatedly and emphatically urges anyone exploring peptides to work with a board-certified physician and obtain them from a legitimate compounding pharmacy where lipopolysaccharide (endotoxin) has been removed, warns that gray/black-market peptides frequently carry LPS that triggers immune responses. This is his single most consistent message.

BPC-157, cancer/angiogenesis cautionwell-sourced

Frames BPC-157 as promising for tissue repair but flags a potential tumor-growth risk because it upregulates VEGF and promotes angiogenesis; says anyone with a known cancer should be very cautious, and stresses that human data is essentially one poorly-conducted study against a large animal-only literature. Recommends cycling off rather than continuous use.

BPC-157, personal use for back injuryfair

Has said he personally used BPC-157 for lower-back pain from an L5 disc issue (deadlifting-related) and that it resolved quickly, outperforming massage/heat/e-stim, while still framing his own use as experimental self-education, not a recommendation.

Growth hormone secretagogues, general cancer/age cautionwell-sourced

States that anytime you augment growth hormone you increase tumor/cancer risk, and questions why anyone under ~30 would augment GH absent a clinical need, a recurring 'growth promotion cuts both ways' caveat applied across the whole GH-peptide category.

CJC-1295, avoidfair

Singles out CJC-1295 negatively, citing an association with cardiovascular death in trials, and says that given decent alternatives (sermorelin, tesamorelin) he doesn't see why anyone would specifically choose CJC-1295.

Ipamorelin, 'cleaner' GH secretagogue (with a downside)fair

Describes ipamorelin as a relatively clean GH secretagogue (raises GH and suppresses somatostatin) but flags that it elevates ghrelin and meaningfully increases hunger; contrasts it with GHRP-2/-6 and hexarelin, which he says push cortisol and prolactin up much more.

Hexarelin, avoid high dosesfair

Warns hexarelin is the most potent GH stimulator but dramatically raises prolactin and can desensitize receptors in a way that could effectively shut down the GH system; says he can't see why anyone would use high doses.

Sermorelin, personal use, then discontinuedwell-sourced

Said he used sermorelin on and off for ~2 years and that it deepened the first half of his night's sleep but suppressed REM in the second half (per his sleep tracker); also reported it consistently raised his PSA, which normalized when he stopped, so he discontinued it. A clear example of him publicly reversing on a peptide based on his own data.

Pinealon. REM-sleep peptide he reports still usingfair

Describes pinealon (with oral glycine, pulsed not nightly) as essentially the only thing he has found that improves his REM sleep, claiming his tracked REM roughly doubled over several months. Presents this as an n-of-1 personal anecdote and notes there is no published human research demonstrating it.

MK-677 (ibutamoren), tried once, disliked itfair

Says he tried MK-677 once and it wrecked his sleep via extreme hunger, describing the appetite effect in starkly negative terms; a one-time trial he did not continue.

Epitalon / longevity peptides, mechanism without human prooffair

Treats epitalon and telomere/longevity peptide claims skeptically: says the mechanistic logic is loosely strung together from animal work, with no human clinical trials, and that the telomere-longevity link itself remains controversial.

Melanocortin peptides (PT-141 / melanotan), melanoma cautionfair

Notes PT-141 (Vyleesi) is FDA-approved for low desire in premenopausal women and used off-label, but lists nausea, flushing, blood-pressure and pigmentation effects, and warns people with melanoma to be very cautious with any peptide that stimulates the melanocortin pathway.

Peptides are pleiotropic, no peptide does one thingwell-sourced

A recurring framing principle: emphasizes that peptides have multiple, often unpredictable effects across many tissues, so single-benefit marketing claims are misleading and effects must be weighed against off-target risks.

Role framing, communicator, not prescriberwell-sourced

Explicitly positions the podcast as zero-cost educational information separate from his Stanford roles, says he is not telling anyone to run out and take any peptide, and frames his own peptide trials as short-term self-experimentation rather than medical advice.

BPC-157 (recovery peptide)thin

Discusses BPC-157 as a tool for healing injuries and tissue repair, but within a framing that the strong evidence is animal/preclinical and human trial data is lacking, i.e., promising mechanism, not proven in humans. He raises it in the injury-recovery context alongside Attia rather than presenting it as a settled therapy.

MK-677 / Ibutamoren (GH secretagogue / ghrelin agonist)fair

Treats ~25 mg/day as the standard dose with diminishing returns above it, and positions MK-677 as a convenient oral alternative to injectable HGH (no needles, no refrigeration, cheaper) that yields results comparable to modest GH doses. Flags real downsides he takes seriously: ravenous appetite that makes cutting impractical, elevated fasted glucose / reduced insulin sensitivity, water retention and joint/muscle aches from raised GH-IGF-1, and lethargy mitigated by dosing pre-bed. Concludes he personally avoids ghrelin mimetics unless eating above maintenance, and advises caution/cycling especially given possible long-term effects of chronic ghrelin elevation.

Bloodwork and biomarker monitoring (his foundational message)fair

His most consistent and repeated position: do not run hormones or compounds blind, get comprehensive bloodwork (testosterone, estradiol, fasting glucose/insulin, lipids including ApoB/particle data, CBC, liver enzymes, blood pressure) and track markers over time. He frames difficulty accessing testing (notably in Canada) as the core problem, and this conviction is the stated reason he co-founded Marek Health. Note the conflict: the business he steers people to sells this testing.

Growth hormone (exogenous HGH)thin

Argues HGH is widely misunderstood and is NOT an 'elixir of life', the benefits are oversold relative to the risks and measurement is tricky. Distinguishes exogenous HGH from secretagogue/peptide approaches to raising endogenous GH, and discusses practical use mainly in the context of tissue repair during a healing phase rather than as a general anti-aging or muscle-building miracle.

No compound is perfectly selective (core PED philosophy)fair

A recurring through-line of his analysis: there is no drug that is purely selective for the effect you want with no off-target consequences, every androgen, SARM, or peptide is a set of trade-offs, so the honest question is risk/benefit and monitoring, not whether something is 'safe.' This anti-hype, side-effects-always-exist posture is consistent across his catalog.

Underground / black-market PED sourcingthin

Openly acknowledges from personal experience the realities of acquiring compounds from underground labs (citing cheap per-vial pricing) and the quality, dosing-accuracy, and purity uncertainty that comes with an unregulated grey market, which he ties back to his insistence on bloodwork to verify what a product is actually doing in your body. He describes the landscape candidly rather than endorsing it as safe.

Reasoning from primary literature (method, not a single claim)fair

Built his reputation on breaking down compounds by citing clinical trials and pharmacology papers rather than gym anecdote, unusually citation-forward for a fitness influencer. This evidence-referencing method is consistent across his blog articles and long-form podcast appearances (e.g., the multi-hour Peter Attia episodes).

Peptides as a category (do they build muscle?)well-sourced

States flatly that there are currently NO peptides that directly build muscle. Frames peptides as signaling agents that bind receptors and trigger biological responses (metabolism, tissue repair) rather than driving hypertrophy the way anabolic steroids do. Backs the claim three ways: mechanism, thin research, and the real-world observation that enhanced pro bodybuilders don't rely on muscle-building peptides because none exist.

Growth-hormone secretagogues (sermorelin, CJC-1295, ipamorelin), 'permissive anabolics'well-sourced

Calls GH secretagogues 'permissive anabolics': they don't cause muscle growth directly, but can support it once training and nutrition are already dialed in, offering marginal improvements in recovery, joint health, and sleep. Explicitly positions them as enhancers of an already-excellent plan, not a shortcut.

Recovery peptides (BPC-157, TB-500)well-sourced

Skeptical and safety-cautious. Groups BPC-157/TB-500 as 'recovery peptides' with mixed results and essentially no human safety data, and raises a mechanistic concern that they could theoretically assist cancer-cell growth if a cancer is already present. Treats them as unproven in humans, not as established healing agents.

Exercise mimetics (MOTS-c) and IGF-1 modulators (IGF-1 LR3/DES, MGF)well-sourced

Wary of both. Describes MOTS-c-type 'exercise mimetics' as promising for aerobic health but severely under-researched and possibly anti-anabolic (mTOR suppression). Says IGF-1 modulators lack real-world anabolic drive and have poor tissue selectivity, making them likely bad for longevity with increased cancer risk.

Animal-vs-human evidence gap (the site's core thesis)well-sourced

Consistently separates mechanistic/animal data from human-outcome data. Notes recovery peptides have 'essentially no human safety data' and exercise mimetics are 'largely unvetted' in human trials, while crediting GLP-1s specifically because they DO have multi-year human data, using the strength of human evidence as the dividing line between classes.

Sourcing / gray-market peptide qualityfair

Warns buyers off careless gray-market purchasing: paraphrased, 'don't just click on things and buy them, beware,' noting peptide shops vary wildly in legitimacy and product quality. Aligns with treating what's actually in the vial as a primary risk.

GLP-1 drugs (semaglutide, tirzepatide, retatrutide)well-sourced

Strongly positive and a personal user. Considers GLP-1s transformative health tools, not cheating; prefers tirzepatide over semaglutide as 'cleaner' with fewer side effects, and is especially enthusiastic about retatrutide, calling it a near 'health elixir' that does much more than suppress appetite (liver fat, inflammation). Flags the core gap: GLP-1s don't selectively burn fat, so users lose muscle alongside fat, and a safe muscle-preserving companion drug is the missing breakthrough.

Activin/myostatin-pathway drugs (e.g., bimagrumab) as future muscle-buildersfair

Sees activin-antagonist / 'release-the-brakes' muscle drugs as the genuinely promising frontier, citing trial data of muscle gain alongside large fat loss, but frames them as enhancers of proper nutrition and training, not replacements, and as still emerging rather than ready.

Anabolic steroids, candor about the downside and his own dose reductionwell-sourced

Openly admits long-term steroid use and publicly walks back high doses. Reports peaking for a 2024 show near ~2,000 mg/wk total androgens, then a year later near ~750 mg/wk with the same or better strength, concluding the extra muscle was 'mostly water.' Candid about the psychological/cognitive 'dark side' on high doses: anxiety, intrusive thoughts, aggression, and reduced fluid intelligence/short-term memory.

Steroids and long-term harm (Peter Attia podcast)fair

On Peter Attia's podcast (Ep. 335) gave candid, experience-based commentary on anabolic-steroid doses, drug combinations, side effects, long-term muscle retention after discontinuation, and the trade-offs of supraphysiologic testosterone, consistent with his broader 'be honest about the risks' posture rather than promotional.

BPC-157 and TB-500 for injury recoveryfair

Says he spot-injects BPC-157 and TB-500 directly into injured areas (his lat, shoulder, etc.) for tissue repair, and characterizes them as being like a 'multivitamin' for a professional bodybuilder because, in his words, you are essentially never not injured somewhere at that level. Frames their use as recovery and health, not as a way to gain a competitive edge.

Thymosin Alpha-1 for autoimmune managementthin

Says he started Thymosin Alpha-1 in 2018 after his autoimmune kidney disease diagnosis for immune regulation, still takes it in cycles through the year, and reports no true autoimmune flare-ups since starting it.

GHK-Cu after shoulder surgerythin

Says he recently added GHK-Cu post-retirement for tissue repair following shoulder/rotator-cuff surgery.

Growth-hormone-releasing peptides for longevitythin

Says he is exploring GH-releasing peptides (ipamorelin, CJC-1295, tesamorelin) post-retirement as longevity/anti-aging options and as an alternative to synthetic growth hormone, after allowing his natural hormone production to recover.

TRT versus anabolic steroids (the distinction)fair

Distinguishes the two: characterizes steroid use as higher doses, more compounds, and more 'underground,' while framing TRT as a legitimate therapeutic option for people over ~35 with genuinely low testosterone, where it can help with energy, body composition, and general health.

Reduced PED use after kidney diagnosiswell-sourced

Says his performance-enhancing drug intake actually DECREASED over his career, he cut it down (reportedly by about half) after his 2018 autoimmune kidney diagnosis, choosing to push his training/work harder rather than rely on drugs, and prioritizing long-term health. Consistent message across multiple years.

IgA nephropathy and health monitoringwell-sourced

Has spoken openly about being diagnosed with IgA nephropathy (an autoimmune kidney disease) around 2018, which caused severe water retention and required prednisone in large doses, and says it pushed him toward routine blood work, physician consultation, and a more health-first, cautious approach to what he puts in his body.

Own historical GH and steroid use (career)well-sourced

Openly admits using anabolic steroids and pharmaceutical growth hormone under medical supervision throughout his competitive career, and says he came off when not competing. In a 2019 interview he further admitted the doses were higher than he had previously listed and that he added insulin specifically in prep for the 1997 Mr. Olympia.

Insulin as the most dangerous PEDwell-sourced

Singles out insulin as a serious health risk in bodybuilding, argues it degrades physique quality and shortens lifespan (citing the roughly 10-years-lower life expectancy of insulin-dependent diabetics), and warns that stacking insulin with steroids makes competitors 'a ticking time bomb,' linking it to heart attacks in men in their 40s-50s.

Modern PED doses vs. the 1990swell-sourced

Contends that today's non-competitive users take far higher doses than 1990s professionals did, citing that he used about 200mg/week of trenbolone at his peak while modern recreational users report ~800mg/week, and frames this escalation as the core health danger.

TRT for older men (and himself)well-sourced

Supports physician-supervised testosterone replacement for men over 40 with genuinely low testosterone, framing it as a health/quality-of-life intervention (says his mental outlook improved within a month), explicitly NOT as a muscle-building tool. Opposes recreational steroid use by young non-athletes.

His current micro-dosed TRT protocolwell-sourced

Says he stays on TRT in retirement at a deliberately low, steady dose, about 20mg/day subcutaneously (~200mg over 10 days, ~600mg/month), for health maintenance rather than size.

Failed HCG experiment (reports negative results)well-sourced

Reports he tried reducing his TRT and adding micro-doses of HCG to stimulate natural production, but felt notably worse and stopped after about two weeks ('felt like shit'), unable to pinpoint why, an example of him publicly sharing an experiment that did not work.

'GH gut' / bloated-waist mythfair

Disputes the popular claim that growth hormone enlarges internal organs to cause the distended-belly look, saying organ scans on himself showed no enlargement; instead points to visceral fat, intestinal water retention, insulin, and IGF-1 as more likely causes, but explicitly hedges that he doesn't really know for certain.

Hormone optimization via professionalsfair

Advocates getting hormones assessed and managed by qualified professionals rather than self-experimenting, framing balanced hormones as the foundation of feeling and performing well in middle age and beyond.

Anabolic gains are temporaryfair

States that muscle gains made through anabolics are a temporary situation contingent on continued use, part of his broader message tempering expectations and downplaying drugs as a shortcut.

Psychedelics / post-career wellness pivotfair

Has become a vocal proponent of ayahuasca and other psychedelics plus yoga and meditation since retiring, describing a transformative experience (a difficult first ayahuasca trip in which he felt told to 'stop poisoning' himself, then a later session leaving him with a sense that everything is connected). Not a peptide position, but defines his current health-and-recovery worldview and is now monetized via retreats.

Named recovery peptides (BPC-157 / TB-500 / GHRPs)thin

GAP / NOT FOUND. No source located shows Yates discussing modern named recovery peptides by name. His 'growth hormone' commentary refers to pharmaceutical hGH from his career, not GH-secretagogue peptides, and should not be presented as a peptide endorsement. Reporting this as an honest absence rather than fabricating a position.